Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma

Aim: Angiopoietin 1 (Ang-1) and its antagonist, angiopoietin 2 (Ang-2), are novel ligands that regulate the Tie2 receptor. The Ang-2 gene is upregulated in the hypervascular type of human hepatocellular carcinoma (HCC). To gain a better understanding of the role of the Ang–Tie2 system in HCC the expression of these genes was investigated in a series of human HCCs. Methods: The expression of the angiopoietin and Tie2 proteins was investigated in nine normal liver tissues and 52 surgically resected HCCs. In addition, the effects of hypoxic stimuli on Ang-1, Ang-2, vascular endothelial growth factor (VEGF), and erythropoietin (EPO) expression was investigated in Hep3B cells. Results: Ang-1, rather than Ang-2, was more frequently expressed in the normal liver. Ang-1 was expressed in 68% of HCCs, whereas Ang-2 was expressed in 81%, and was significantly higher in poorly differentiated HCCs characterised by high vascularity (p = 0.02), and in tumours with a peliotic change (p = 0.02). Strong expression of Tie2 was seen in tumour vessels in accordance with Ang-2 expression. In Hep3B cells, hypoxic stimuli upregulated VEGF and EPO, but not Ang-1 or Ang-2. Conclusions: These data support the evidence that the reversal of Ang-1 and Ang-2 expression plays an important role in the angiogenic and dedifferentiation processes in HCC. The hypoxic stimuli were not responsible for Ang-2 upregulation, unlike that of VEGF, in human HCC cells.

[1]  A. Harris,et al.  Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel‐Lindau gene and hypoxia , 2002, The Journal of pathology.

[2]  J. Le Bas,et al.  Immunohistochemical study of VEGF, angiopoietin 2 and their receptors in the neovascularization following microinjection of C6 glioma cells into rat brain. , 2002, Anticancer research.

[3]  K. Sugimachi,et al.  Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma , 2002, Hepatology.

[4]  L. Ellis,et al.  Differential expression of angiopoietin‐1 and angiopoietin‐2 in colon carcinoma , 2001, Cancer.

[5]  T. Suda,et al.  Role for Angiogenesis Expression of Angiopoietin-2 in Human Glioma Cells and Its Updated Version , 2001 .

[6]  K. Alitalo,et al.  Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. , 2001, Cardiovascular research.

[7]  Andrew L. Kung,et al.  Suppression of tumor growth through disruption of hypoxia-inducible transcription , 2000, Nature Medicine.

[8]  Ji-Hye Kim,et al.  Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway , 2000, Oncogene.

[9]  G. Krikun,et al.  Expression of angiopoietin-2 by human endometrial endothelial cells: regulation by hypoxia and inflammation. , 2000, Biochemical and biophysical research communications.

[10]  G. Semenza,et al.  HIF-1 and human disease: one highly involved factor. , 2000, Genes & development.

[11]  H. Dvorak,et al.  Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. , 2000, The American journal of pathology.

[12]  B. Bussolati,et al.  Angiopoietin-1 and angiopoietin-2 activate trophoblast Tie-2 to promote growth and migration during placental development. , 2000, The American journal of pathology.

[13]  Thomas N. Sato,et al.  Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. , 1999, Science.

[14]  G. Yancopoulos,et al.  New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF , 1999, Oncogene.

[15]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[16]  K. Suzuma,et al.  Hypoxia and Vascular Endothelial Growth Factor Selectively Up-regulate Angiopoietin-2 in Bovine Microvascular Endothelial Cells* , 1999, The Journal of Biological Chemistry.

[17]  M. Makuuchi,et al.  Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. , 1999, The Journal of clinical investigation.

[18]  K. Plate,et al.  Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. , 1998, The American journal of pathology.

[19]  M. Kojiro,et al.  Expression of vascular endothelial growth factor in human hepatocellular carcinoma , 1998, Hepatology.

[20]  Douglas Hanahan,et al.  Signaling Vascular Morphogenesis and Maintenance , 1997, Science.

[21]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[22]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[23]  J. Gleadle,et al.  Induction of hypoxia-inducible factor-1, erythropoietin, vascular endothelial growth factor, and glucose transporter-1 by hypoxia: evidence against a regulatory role for Src kinase. , 1997, Blood.

[24]  Pamela F. Jones,et al.  Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.

[25]  Pamela F. Jones,et al.  Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.

[26]  K. Shirabe,et al.  Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. , 1996, Gastroenterology.

[27]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[28]  H. Honda,et al.  CD34 expression in endothelial cells of small hepatocellular carcinoma: Its correlation with tumour progression and angiographic findings , 1995, Journal of gastroenterology and hepatology.

[29]  Thomas N. Sato,et al.  Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Hirohashi,et al.  Phenotype changes in tumor vessels associated with the progression of hepatocellular carcinoma. , 1993, Japanese journal of clinical oncology.

[31]  J. Rossant,et al.  tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. , 1992, Oncogene.

[32]  J. Partanen,et al.  A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains , 1992, Molecular and cellular biology.

[33]  K. Shirabe,et al.  Angiographically undetected small hepatocellular carcinoma: Clinicopathological characteristics, follow‐up and treatment , 1989, Hepatology.

[34]  R. Macsween.  Pathology of the Liver , 1981 .

[35]  H. Naora,et al.  Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway. , 2002, Anticancer research.

[36]  Zheng Qi-chang.  Expression of angiopoietin-2 gene and its receptor Tie2 in hepatocellular carcinoma , 2001 .

[37]  W. Risau,et al.  Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the Angiopoietin receptor Tie-2 , 1999, Oncogene.

[38]  P. Rao,et al.  Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. , 1998, British Journal of Cancer.

[39]  日本肝癌研究会.  Classification of primary liver cancer , 1997 .

[40]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[41]  Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. , 1990, Annals of surgery.

[42]  W. G. Hardy,et al.  Vascular disorders. , 1968, Progress in neurology and psychiatry.